ConvaTec Achieves Strong Financial Results, Predicts Double-Digit Growth
Update: 2025-11-13
Description
ConvaTec Group, a medical technology company, reported robust financial results, with a 6.3% organic revenue growth for the first ten months of 2022. They narrowed their full-year prediction to 6.0-6.5% growth, excluding InnovaMatrix. New product launches, such as ConvaFoam and Esteem Body, drove success across chronic care categories like Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. ConvaTec anticipates double-digit growth in adjusted earnings per share and further profit margin improvements in 2023, with organic growth in non-InnovaMatrix sales expected to be between 5-7%.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
